Mind Medicine (MindMed) Inc. (MNMD) Income Statement Analysis

See more : Unizyx Holding Corporation (3704.TW) Income Statement Analysis – Financial Results

Complete financial analysis of Mind Medicine (MindMed) Inc. (MNMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mind Medicine (MindMed) Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Domino’s Pizza Enterprises Limited (DMZPY) Income Statement Analysis – Financial Results
West Coast Ventures Group Corp. (WCVC) Income Statement Analysis – Financial Results
Kernel Holding S.A. (KARNF) Income Statement Analysis – Financial Results
Polskie Górnictwo Naftowe i Gazownictwo S.A. (PGN.WA) Income Statement Analysis – Financial Results
Advantis Corp. (ADVT) Income Statement Analysis – Financial Results

Mind Medicine (MindMed) Inc. (MNMD)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.mindmed.co

About Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	3.16M	3.22M	2.62M	0.00	6.68K	6.68K	5.50K	0.00	0.00
Gross Profit	-3.16M	-3.22M	-2.62M	0.00	-6.68K	-6.68K	-5.50K	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	48.96M	36.17M	34.79M	18.63M	0.00	0.00	0.00	0.00	0.00
General & Administrative	41.74M	30.16M	59.07M	14.40M	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	41.74M	30.16M	59.07M	14.40M	461.50K	855.26K	1.23M	111.25K	94.55K
Other Expenses	0.00	2.00K	106.00K	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	93.87M	66.33M	93.85M	33.03M	461.50K	855.26K	1.23M	111.25K	94.55K
Cost & Expenses	93.87M	66.33M	93.85M	33.03M	468.18K	861.94K	1.24M	111.25K	94.55K
Interest Income	4.66M	1.50M	0.00	0.00	0.00	4.00K	8.40K	1.20K	1.90K
Interest Expense	0.00	1.50M	359.00K	164.00K	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	3.16M	3.22M	2.62M	206.30K	6.68K	6.68K	5.50K	0.00	0.39
EBITDA	-92.57M	-53.57M	-91.22M	-33.77M	-1.11M	-851.26K	-1.51M	-111.25K	-92.66K
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-93.87M	-66.33M	-96.36M	-33.03M	-468.18K	-861.94K	-1.24M	-111.25K	-94.55K
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	-1.87M	9.54M	-339.00K	-907.00K	-647.63K	4.00K	8.40K	-68.65K	1.89K
Income Before Tax	-95.73M	-56.80M	-94.19M	-33.94M	-1.12M	-857.94K	-1.23M	-179.90K	-92.66K
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	-9.54M	-1.16M	164.00K	-3.69	-1.91	-1.70	0.00	-0.39
Net Income	-95.73M	-47.26M	-93.04M	-34.10M	-1.12M	-857.94K	-1.23M	-179.90K	-92.66K
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-2.44	-1.53	-3.40	-1.92	-2.94	-2.74	-4.85	-2.24	-1.17
EPS Diluted	-2.44	-1.53	-3.40	-1.92	-2.94	-2.74	-4.85	-2.24	-1.17
Weighted Avg Shares Out	39.16M	30.86M	27.38M	17.75M	379.41K	312.55K	252.82K	80.42K	79.00K
Weighted Avg Shares Out (Dil)	39.16M	30.86M	27.38M	17.75M	379.41K	312.55K	252.82K	80.42K	79.00K

Mind Medicine (MindMed), Inc. (MNMD) Q3 2022 Earnings Call Transcript

November 10, 2022seekingalpha.com

Mind Medicine (MindMed), Inc. (NASDAQ:MNMD ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Robert Barrow - CEO & Director Schond Greenway - CFO Daniel Karlin - Chief Medical Officer Conference Call Participants Charles Duncan...